Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Koninklijke Philips NV (PHG) Price & Performance

JPMorgan Nasdaq Equity Premium Income ETFTrade
Koninklijke Philips NVTrade

Price performance (Past 24H)

Key statistics

JPMorgan Nasdaq Equity Premium Income ETF vs Koninklijke Philips NV — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.68, while Koninklijke Philips NV trades at $26.58 (market cap $26.19B). The key difference: Koninklijke Philips NV pays a 3.79% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Koninklijke Philips NV nearer its low. Which is the better fit depends on your goals.

JEPQPHG
Sector
Income / Options OverlayHealth
52-Week High
$61.46$32.91
52-Week Low
$53.77$24.54
Market Cap
$26.19B
Enterprise Value
$32.46B
Dividend Yield
3.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ trades at $58.59, up 0.14% with a bearish technical signal from moving averages. The ETF focuses on Nasdaq-100 exposure with covered-call strategies, generating monthly income through dividends. Recent distributions include $0.64, $0.56, and $0.59 per share, highlighting its income-oriented approach. Technical indicators show neutral oscillators but overall bearish momentum with key support at $57.

The outlook remains cautious due to technical bearishness and capped upside from covered calls. Investment appeal centers on high distribution yields for income-focused investors, though performance may lag pure Nasdaq-100 ETFs during rallies. Risks include strategy underperformance in bull markets and dependency on options income sustainability.

Koninklijke Philips NV

PHG trades at $26.80, down 0.56% with bearish technical signals. The company shows improved fundamentals with net income turning positive to $895M in 2025 after previous losses, though revenue declined slightly to $17.83B. Analyst consensus is mixed with 40.9% buy ratings but technical indicators show selling pressure. Recent developments include FDA clearances for AI-powered medical devices and strategic healthcare partnerships.

PHG presents a turnaround story with profitability recovery but faces execution risks amid competitive pressures. The stock offers value at reasonable valuations (P/E 23.67, P/S 1.29) but requires monitoring of revenue stabilization and AI product adoption. Near-term catalyst includes Q2 2026 earnings with expected EPS of $0.40.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About JPMorgan Nasdaq Equity Premium Income ETF

JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.

Read more on JEPQ

About Koninklijke Philips NV

Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.

Read more on PHG